<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01228942</url>
  </required_header>
  <id_info>
    <org_study_id>15248</org_study_id>
    <nct_id>NCT01228942</nct_id>
  </id_info>
  <brief_title>A Prospective Trial of COXEN Chemotherapy Prediction</brief_title>
  <official_title>A Prospective Trial of COXEN Chemotherapy Prediction in Persistent and Recurrent Ovarian, Fallopian Tube, and Peritoneal Carcinomas</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Virginia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Virginia</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if the COXEN algorithm, using the diagnostic device
      Affymetrix GeneChip, is able to predict which chemotherapies will be best for treatment of
      recurrent or persistent ovarian, fallopian tube, or primary peritoneal cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The current proposal seeks to apply and extend this novel genomic prediction technique to
      finding better chemotherapeutic options for recurrent ovarian cancer using individual
      patients' gene-expression signatures of chemosensitivity. The utility of the COXEN technique
      has been validated and found to accurately predict 1) the chemosensitivity of an independent
      panel of 40 bladder cancer cell lines; 2) activity of each of the &gt;45K candidate compounds in
      the NCI-60 drug screening database, which resulted in the identification of a
      highly-effective novel compound for bladder cancer and patients' responses and survival on 12
      historical clinical trials of combination chemotherapy. In particular, the GEMs of breast
      cancer can be used to stratify both clinical response and overall patient survival with a
      striking difference between the predicted responders vs. predicted non-responders in 5
      independent chemotherapeutic trials of breast cancer. The next step is to test the prediction
      model in recurrent ovarian cancer.
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Lack of funding/resources
  </why_stopped>
  <start_date>October 2010</start_date>
  <completion_date type="Actual">June 2013</completion_date>
  <primary_completion_date type="Anticipated">October 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>overall response rate</measure>
    <time_frame>12 months</time_frame>
    <description>patient will have CT scans and CA 125 drawn to track response to chemotherapy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>subject lifetime</time_frame>
    <description>patient will be tracked for life</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Ovarian Neoplasms</condition>
  <condition>Fallopian Tube Neoplasms</condition>
  <arm_group>
    <arm_group_label>Platinum Sensitive</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Treatment with platinum-based therapy; COXEN prediction model chooses secondary agent if doublet</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Platinum resistent</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>single agent based on Coxen prediction model</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>COXEN analysis for chemotherapy prediction</intervention_name>
    <description>Using the affymetrix genechip along with the COXEN algorithm the subject's treatment will be determined</description>
    <arm_group_label>Platinum Sensitive</arm_group_label>
    <arm_group_label>Platinum resistent</arm_group_label>
    <other_name>Affymetrix genechip</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age greater than 18

          -  diagnosis of recurrent, persistent, refractory ovarian, fallopian or primary
             peritoneal cancer

          -  tumor tissue, ascites or pleural fluid available for biopsy

          -  life expectancy greater than 6 months

        Exclusion Criteria:

          -  patients with borderline or low malignant histologies

          -  patients with a history of other malignancies within last 5 years
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>95 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Linda Duska, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Virginia</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>June 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 20, 2010</study_first_submitted>
  <study_first_submitted_qc>October 25, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 27, 2010</study_first_posted>
  <last_update_submitted>June 5, 2014</last_update_submitted>
  <last_update_submitted_qc>June 5, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 6, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Virginia</investigator_affiliation>
    <investigator_full_name>Linda R Duska</investigator_full_name>
    <investigator_title>Medical Attending</investigator_title>
  </responsible_party>
  <keyword>ovarian cancer</keyword>
  <keyword>fallopian tube cancer</keyword>
  <keyword>primary peritoneal cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Fallopian Tube Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

